Régression de carcinomes basocellulaire et épidermoïde cutanés sous pembrolizumab

Delaitre, L.; Martins-Héricher, J.; Truchot, E.; Denis, D.; Prophette, B.; Maillard, H.; Beneton-Benhard, N.

doi:10.1016/j.annder.2019.10.031

Cited by 10 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment methods for BD include topical therapies (5-fluorouracil (5-FU), imiquimod), cryotherapy (cryosurgery), curettage with cautery, PDT, standard surgical excision, Mohs micrographic surgery, laser (CO 2 laser, non-ablative neodymium: YAG), radiotherapy, systemic treatments, and combination therapy ( 5 ). Some novel treatment approaches, such as pembrolizumab (a humanized monoclonal anti-PD-1 antibody for the treatment of melanoma and other malignancies) ( 17 , 18 ) and thermotherapy ( 19 ), have also been tried for the treatment of BD. Previous studies reported that the complete clearance rate can reach 94.40% when the surgical margin is 5 mm ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical and histopathological characteristics, diagnosis and treatment, and comorbidities of Bowen’s disease: a retrospective study

Zhou,

Jiang,

Zhang

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundBowen’s disease (BD) is a slow-growing precancerous skin condition, often concurrent with other diseases, with a high misdiagnosis rate. Previous studies show that patients with BD in different populations have differentiated characteristics.Materials and methodsA retrospective study was conducted in a tertiary hospital in Shenzhen, China. Data about demographic information, diagnosis and treatment, clinical and pathological characteristics, and comorbidities of 50 patients with BD were collected and analyzed.ResultsClinical data of onset age and disease course of 43 patients with BD were available, the average onset age of male and female patients are 55.1 (standard deviation (SD) = 15.29) and 58.2 (SD = 15.59) years old, respectively; the average disease course of male and female patients are 25.3 (SD = 28.63) and 33.9 (SD = 49.65) months, respectively. The onset age (p = 0.52) and disease course (p = 0.49) between male and female patients are not significantly different. Interestingly, there is a negative correlation between onset age and disease course (r = −0.245, p = 0.11). The correct rate of clinical diagnosis is relatively low (54.00%); Some patients with BD are misdiagnosed as Bowenoid papulosis (10.00%), actinic keratosis (8.00%), basal cell carcinoma (8.00%), seborrheic keratosis (6.00%), and pigmented naevus (4.00%). Trunk and limbs are the most common distribution sites of BD lesions, and 94.00% patients with BD are treated with surgical resection; 66.00% patients with BD had comorbidities, including skin diseases (48.48%), cardiovascular diseases (39.39%), gastrointestinal diseases (30.30%), respiratory diseases (27.27%), and tumors (18.18%). The most commonly observed histopathological characteristics of BD are squamous-cell hyperplasia (86.00%), disordered maturation with atypical keratinocytes (74.00%), atypical mitoses (60.00%), hyperkeratosis with hypokeratosis (48.00%), dermal inflammatory cell infiltration (36.00%), and koilocytosis (22.00%).ConclusionBD often occurs in middle-aged and elderly people and is easily misdiagnosed. The onset age and disease course of patients with BD are not significantly different between males and females, whereas there is a negative correlation between the onset age and disease course. BD is more likely to occur in trunk and limbs in the Chinese population, and most patients with BD are concurrent with comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and histopathological characteristics, diagnosis and treatment, and comorbidities of Bowen’s disease: a retrospective study

Zhou,

Jiang,

Zhang

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…No AEs were observed. Delaitre et al described the case of a patient with locally advanced cSCC on the scalp and BCC on the nose who received pembrolizumab 2 mg/kg Q3W [81]. A CR of the cSCC and BCC was observed after 11 cycles and 7 cycles, respectively.…”

Section: Pembrolizumabmentioning

confidence: 99%

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Wessely

Steeb

Leiter

et al. 2020

IJMS

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer that predominantly arises in chronically sun-damaged skin. Immunosuppression, genetic disorders such as xeroderma pigmentosum (XP), exposure to certain drugs and environmental noxae have been identified as major risk factors. Surgical removal of cSCC is the therapy of choice and mostly curative in early stages. However, a minority of patients develop locally advanced tumors or distant metastases that are still challenging to treat. Immune checkpoint blockade (ICB) targeting CTLA-4, PD-L1 and PD-1 has tremendously changed the field of oncological therapy and especially the treatment of skin cancers as tumors with a high mutational burden. In this review, we focus on the differences between cSCC and cutaneous melanoma (CM) and their implications on therapy, summarize the current evidence on ICB for the treatment of advanced cSCC and discuss the chances and pitfalls of this therapy option for this cancer entity. Furthermore, we focus on special subgroups of interest such as organ transplant recipients, patients with hematologic malignancies, XP and field cancerization.

show abstract

Perspectives of Immunotherapy in Non-Melanoma Skin Cancers

Rubatto

Fava

Avallone

et al. 2021

New Therapies in Advanced Cutaneous Malignancies

View full text Add to dashboard Cite

Régression de carcinomes basocellulaire et épidermoïde cutanés sous pembrolizumab

Cited by 10 publications

References 23 publications

Clinical and histopathological characteristics, diagnosis and treatment, and comorbidities of Bowen’s disease: a retrospective study

Clinical and histopathological characteristics, diagnosis and treatment, and comorbidities of Bowen’s disease: a retrospective study

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Perspectives of Immunotherapy in Non-Melanoma Skin Cancers

Contact Info

Product

Resources

About